Avalyn Pharma Inc. Common Stock

AVLN | NASDAQ

$26.05

+$0.42 (+1.64%)

Nov 2, 2026, 9:55 AM ET · Market open

Fiscal Quarter Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026
Cash & Equivalents	264.2M	92.31M
Short-Term Investments	88.23M	30.82M
Long-Term Investments	61.1M	n/a
Other Long-Term Assets	3.23M	3M
Receivables	1.67M	253K
Inventory	n/a	n/a
Other Current Assets	n/a	2.73M
Total Current Assets	357.77M	129.99M
Property-Plant & Equipment	3.35M	2.68M
Goodwill & Intangibles	n/a	n/a
Total Long-Term Assets	67.68M	5.68M
Total Assets	425.45M	135.66M
Account Payables	2.65M	3.15M
Deferred Revenue	n/a	n/a
Short-Term Debt	816K	n/a
Other Current Liabilities	4.17M	1.84M
Total Current Liabilities	10.81M	11.79M
Long-Term Debt	14.8M	14.81M
Other Long-Term Liabilities	n/a	372.22M
Total Long-Term Liabilities	16.29M	388.12M
Total Liabilities	27.1M	399.91M
Total Debt	17.11M	16.41M
Book Value	398.35M	-264.25M
Book Value Per Share	8.99	-6.32
Common Stock	67K	24K
Retained Earnings	-321.17M	-292.23M
Comprehensive Income	-95K	12K
Shareholders Equity	398.35M	-264.25M
Total Investments	149.33M	30.82M